BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Rznomics Advances High-Efficiency Circular RNA Production with Engineered STS Technology

Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in t...

September 08, 2026 | News

AstraZeneca Secures US FDA Approval for ETCAMAH Combination in Advanced Breast Cancer

Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an e...

September 08, 2026 | News

Evinova, Lothar Medical Partner to Digitise Respiratory Clinical Trials

Evinova, a global leader in AI-native clinical development technology, announced a strategic partnership with Lothar Medical to help transform the ex...

September 08, 2026 | News

US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer

FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development Acepodia (6976: TT)...

September 07, 2026 | News

AtomVie Opens $160M Radiopharmaceutical Manufacturing Facility in Canada

AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, cele...

September 07, 2026 | News

Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial

Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...

September 04, 2026 | News

Norroy Bioscience Secures China Clearance for Phase III Trial of PSMA-Targeted Radiopharmaceutical

NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regu...

September 04, 2026 | News

Alteogen, Novartis Ink Up to $3.2B Deal for Subcutaneous Biologics Using ALT-B4

Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreem...

September 04, 2026 | News

EpiVax Adds AI-Enabled Enhancements to ISPRI Immunogenicity Risk Platform

EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the ...

September 04, 2026 | News

Food, Drug, or Neither

Yesterday was the deadline. Japan's Consumer Affairs Agency has stated that the revised labelling provisions and mandatory Good Manufacturing Practice sta...

September 03, 2026 | Analysis

Genprex Selects Andelyn Biosciences to Scale Up AAV Gene Therapy for Diabetes

Andelyn Biosciences, a leading contract development and manufacturing organization, announced that Genprex, Inc. has selected Andelyn to support scale-up m...

September 03, 2026 | News

IDT and Ansa Expand Global Access to Complex DNA Synthesis Through Integrated Ordering

Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options Global adoption growing with more than 400...

September 03, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

September 03, 2026 | News

US FDA Grants Fast Track Designation to T-MAXIMUM’s Allogeneic CAR-T Therapy for Recurrent Glioblastoma

T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation ...

September 02, 2026 | News

Stay Connected